Announcement for the changes in the numbers of shares and their fair value held in the Company’s portfolio as well as the Company’s BVPS and cash balance.

1.Date of occurrence of the event:2023/10/06

2.Company name:Diamond Biofund Inc.

3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office.

4.Reciprocal shareholding ratios:N/A

5.Cause of occurrence: In accordance with the official letter No.1121802934 issued by Taiwan Stock Exchange Corporation on 2023/06/29. The Company is required to announce for the changes in the numbers of shares held in the Company’s portfolio, changes in their fair value and the company’s book value per share and cash and cash equivalent balances on a monthly basis.

6.Countermeasures:

(1)The Company’s changes in the numbers of the protfolio’s shares held by the Company and changes in their fair value in September,2023 are as follows:

(Units:shares; NT$ thousand)

Changes in

Numbers of Numbers of the numbers
shares held shares held of
Portfolio by the by the protfolio’s Changes in
company Company on Company on shares held fair value
2023/09/30 2023/08/31 by the
Company

————— ———– ———– ———– ———-

Oneness Biotech 25,421,128 25,581,128 (160,000) (610,643)
Co., Ltd.

CHO Pharma 30,869,000 30,869,000 – 344,189
Inc.

StemCyte 13,433,150 13,433,150 – (46,613)
International
Ltd.

Original 1,211,761 1,211,761 – (254)
BioMedicals
Co., Ltd.

Theia Medical 9,042,648 9,042,648 – 1,286
Technology Co.
Ltd.

Sinew Pharma 6,725,209 6,725,209 – (40,620)
Inc.

EyeYon 59,018 59,018 – 2,618
Medical Ltd.

Tetanti 7,900,000 7,900,000 – (11,771)
AgriBiotech
Inc.

Kendall N/A N/A N/A 867
Capital
Partners I, L.P

Bilayer 909,090 909,090 – (1,695)
Therapeutics,
Inc.

ImmunAdd Inc. 4,259,999 4,259,999 – –

Other N/A N/A N/A 410

———————————————————————–

Total (361,226)

===========

(2)The Company’s book value per share and cash and cash equivalent balances

are as follows:

Cash and cash
Book value equivalent
Date per share(NT$) (NT$ thousand)

————- ————– —————-

2023/09/30 14.91 4,479,282

7.Any other matters that need to be specified (the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.): The Company’s main investment area is biotechnology, whose stock price and fair value is greatly affected by research and development results, causing relatively large fluctuations. Therefore, if the fair value of the protfolio declines in the current year, the Company’s operating revenue may be negative.